<DOC>
	<DOCNO>NCT00125918</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness tadalafil treatment pulmonary arterial hypertension .</brief_summary>
	<brief_title>PHIRST-1 : Tadalafil Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter study . The key measure effectiveness study drug determine use 6-minute walk test . Eligible patient treat 16 week may eligible enter 52-week extension phase study ( PHIRST-2 ) . Study procedures study ( PHIRST-1 PHIRST-2 ) include routine blood test , medical history , physical exam , questionnaire response , exercise test .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>At least 12 year age . Body weight least 40 kg ( approximately 88 pound ) . Pulmonary hypertension ( PAH ) either idiopathic ; relate collagen vascular disease ; relate anorexigen use ; associate atrial septal defect ( rest SaO2 great equal 88 % ) ; surgical repair , least 1 year duration , congenital systemictopulmonary shunt . If bosentan , must maximal dose 125 mg twice daily minimum 12 week prior screen AST/ALT le 3 time normal . History PAH establish rest mean pulmonary artery pressure great equal 25 mm Hg , pulmonary artery wedge pressure less equal 15 mm Hg , pulmonary vascular resistance great equal 3 Wood unit via right heart catheterization Have World Health Organization functional class I , II , III IV status . Have qualify 6minute walk test distance screen Have evidence significant parenchymal lung disease Are nurse pregnant . PAH due condition note inclusion criterion . History leftsided heart disease . History atrial septostomy within 3 month study entry History angina pectoris condition treat longor shortacting nitrate within 12 week administration study drug . History symptomatic coronary disease . Have therapy prostacyclin analogue , Larginine , phosphodiesterase ( PDE ) inhibitor , investigational drug within 4 week administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Hypertension , Pulmonary ; Pulmonary Heart Disease</keyword>
</DOC>